Dr. Hu’s research interests include drug development and translational cancer pharmacology, and her current projects are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy. The overall goal of her research is to evaluate the role of solute carriers in cancer drug-induced toxicity profiles, in particular peripheral neuropathy. In addition, she aims to identify chemical inhibitors of critical transporters, and explore novel strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.
- PhD, Pharmaceutical Sciences, West Virginia University
- Dean's Innovative Research Award, 2019
- Hu S, Huang KM, Adams EJ, Loprinzi CL, and Maryam Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019 May 23. doi: 10.1158/1078-0432.CCR-18-2152.
- Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, and Nies A. Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1). Clin Pharmacol Ther. 2019 doi: 10.1002/cpt.1588.
- Drenberg CD, Shelat A, Orwick SJ, Li M, Jeon JY, Hu S, Buelow DR, Pioso M, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD. Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML). Nature Commun. 2019 10(1):2189.
- Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51.
- Hu S, Sprowl J. Strategies to reduce solute carrier-mediated toxicity. Clin Pharmacol Ther. 2018 104(5):799-802.
- View all journal articles